Boston Financial Mangement LLC Increases Stake in Astrazeneca PLC (NYSE:AZN)

Boston Financial Mangement LLC boosted its stake in Astrazeneca PLC (NYSE:AZN) by 6.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,447 shares of the company’s stock after buying an additional 7,642 shares during the period. Boston Financial Mangement LLC’s holdings in Astrazeneca PLC were worth $4,311,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Tompkins Financial Corp raised its position in Astrazeneca PLC by 67.0% in the first quarter. Tompkins Financial Corp now owns 3,545 shares of the company’s stock valued at $100,000 after buying an additional 1,422 shares during the period. Meeder Asset Management Inc. purchased a new position in Astrazeneca PLC during the second quarter valued at approximately $105,000. Salem Investment Counselors Inc. purchased a new position in Astrazeneca PLC during the first quarter valued at approximately $107,000. Tower Research Capital LLC TRC raised its position in Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock valued at $121,000 after buying an additional 3,782 shares during the period. Finally, Quadrant Capital Group LLC raised its position in Astrazeneca PLC by 157.1% in the first quarter. Quadrant Capital Group LLC now owns 4,591 shares of the company’s stock valued at $138,000 after buying an additional 2,805 shares during the period. Hedge funds and other institutional investors own 14.30% of the company’s stock.

Astrazeneca PLC (NYSE:AZN) opened at 29.12 on Friday. The firm has a market capitalization of $73.73 billion, a PE ratio of 19.10 and a beta of 0.74. The company has a 50 day moving average of $31.67 and a 200 day moving average of $31.48. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60.

Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same period last year, the firm posted $0.83 EPS. Astrazeneca PLC’s quarterly revenue was down 9.9% on a year-over-year basis. Analysts forecast that Astrazeneca PLC will post $1.86 EPS for the current year.

The company also recently disclosed a None dividend, which will be paid on Monday, September 11th. Investors of record on Friday, August 11th will be given a $0.44 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is 44.92%.

TRADEMARK VIOLATION NOTICE: “Boston Financial Mangement LLC Increases Stake in Astrazeneca PLC (NYSE:AZN)” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2017/08/19/astrazeneca-plc-nyseazn-shares-bought-by-boston-financial-mangement-llc-updated-updated.html.

Several research analysts recently commented on the stock. Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. BidaskClub lowered shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Cowen and Company reiterated a “hold” rating and set a $34.00 price objective on shares of Astrazeneca PLC in a research note on Friday, July 28th. Morgan Stanley lowered shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, July 28th. Finally, Barclays PLC reiterated an “overweight” rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $33.39.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

What are top analysts saying about Astrazeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Astrazeneca PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit